The management of men with prostate cancer (PCa) with biochemical recurrence following local definitive therapy remains controversial. Early use of androgen deprivation therapy (ADT) leads to significant side effects.
STOCKHOLM, SWEDEN (UroToday.com) - The purpose of this multi-institutional study was to evaluate the immunological response in relation to known molecular subtypes of urothelial carcinoma (UC), and also to evaluate the prognostic impact of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in tissue specimens from UC patients.
Immune checkpoint molecules, such as PD-1/PD-L1, are reported to be closely associated with suppression of antitumor immunity, and their inhibitors have been used to treat various cancers including bladder cancer.
Background: Bladder cancer is a common malignancy that affects the human urinary tract. Muscle-invasive bladder cancer (MIBC) is aggressive and has poor prognosis. Previous studies have reported that the tumor-infiltrating lymphocytes (TILs) were associated with MIBC outcome; however, inconsistency remains and mRNA level TIL markers' prognostic significance in MIBC is unclear.
Penile squamous cell carcinoma (SCC) is primarily treated by surgical resection. Locally advanced and metastatic disease require a multidisciplinary treatment approach. However, mortality and morbidity remain high and novel molecular and immunotherapeutic targets are actively being sought.
Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although Sipuleucel-T represented the first successful vaccine for the treatment of established cancer, other immunotherapeutic approaches for prostate cancer such as checkpoint inhibitors have been relatively disappointing to date.
Drugs blocking programmed death ligand-1 (PD-L1) have shown unprecedented activity in metastatic and unresectable bladder cancer. The purpose of the present study was to investigate the expression, clinical significance and association of PD-L1 with tumor-infiltrating lymphocytes (TIL) in resectable urothelial cell carcinoma of the bladder (UCB).
This study aimed to evaluate the density of CD8+ and CD3+ tumor-infiltrating lymphocytes (TILs) and determine whether the immunoscore has any prognostic effect on the oncological outcomes in patients with clear cell renal cell carcinoma (RCC).
Among renal cell carcinoma (RCC) the tumor immune microenvironment has been best characterized in clear cell RCC. In this study we investigated the expression of several immune markers including PD-L1, FOXP3, and CD8 in primary and metastatic papillary RCC.
Login to update email address, newsletter preferences and use bookmarks.